BioSpace News Archive

Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, provided a business update and reported financial results for the third quarter ended September 30, 2019.

Move over lengthy approval process, a new partnership between CEFALY Technology and QB Medical, Inc. means waiting for migraine relief will be quicker, and less of a headache for active military and their dependents.

Biogen Inc. (Nasdaq: BIIB) today announced a new proposed transaction with Samsung Bioepis Co., Ltd. to secure the exclusive rights to commercialize two new ophthalmology biosimilars, SB11 referencing Lucentis®1 and SB15 referencing Eylea®2, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia.

The Inducement Awards were made outside of the company’s current equity plan, but are subject to terms and conditions generally consistent with those in the company’s 2016 Equity Incentive Plan.

Soliant primarily provides therapists, including speech pathologists, psychologists, occupational therapists and nurses, to K-12 schools.

The company will also host a conference call on Thursday, November 14, 2019 at 8:30 a.m. Eastern Time.

Agreement with Biogen covers Samsung Bioepis’ biosimilar candidates in pre-clinical and clinical development, which reference two widely-used biologic medicines in ophthalmology: ranibizumab and aflibercept

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 14, 2019 to report its third quarter 2019 financial results and provide a corporate update.

Equillium, Inc. (Nasdaq: EQ), today announced that data describing the roles of the CD6-ALCAM pathway in systemic lupus erythematosus (SLE) and lupus nephritis will be presented in an oral presentation and two posters at the 2019 American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) Annual Meeting being held November 8-13, 2019 in Atlanta, GA.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today issued the following statement clarifying November 17, 2019 as the true deadline for Velan Capital L.P.’s (“Velan”) consent solicitation.